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measure cost-effectiveness. RESULTS: The total costs for the
average patient are lower when using menotrophin (DKK
13,324; 95%CI: 12,583–14,282) compared with rFSH (DKK
15,852; 95%CI: 15,164–16,614). Furthermore, the cost per clin-
ical pregnancy was lower with menotrophin (DKK 59,282;
95%CI: 50,207–72,056) compared with rFSH hormone (DKK
82,474; 95%CI: 68,389–102,867). Menotrophin is therefore less
expensive both to the patient as well as to the health care sector.
A result which was supported by a bootstrap analysis with 1000
replications. Use of menotrophin can result in savings up to 16
million DKK on the drug budget per year. Savings that could
ﬁnance 1400 additional IVF cycles. CONCLUSION: The analy-
sis has shown that menotrophin compared with rFSH is a cost-
effective choice that is rational to the society and to the health
care sector leading to savings to the patient and the drug budget.
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OBJECTIVES: RIX4414, an oral live-attenuated human
rotavirus (RV) vaccine, has shown to be highly protective against
RV gastroenteritis. The question rises whether the implementa-
tion of vaccination is a cost-effective (CE) management strategy.
METHODS: An economic modelling exercise was performed to
evaluate the CE of vaccination in a Belgian setting. The model
used a Markov process tree, the cycle length was one month with
a lifetime horizon. Effect of seasonality of the infection and of
breastfeeding protection was captured through the model. Acute
diarrhoea events were recorded until the age of 5. Assumed was
that the risk for acute RVGE rapidly decreases after age 5 due
to the acquired natural immunity. Estimates on RV epidemiol-
ogy were obtained from Belgian databases and literature. QALY
was the overall effect measure. Utility-score estimates for age-
groups and health states were obtained through the EQ-5D from
a UK study. The vaccine effect was as reported from phase IIIb
European trial (102247-NTC0014686). Annual discount rates
for cost and effect measures were 3% and 1.5%, respectively.
100% coverage was assumed in base-case analysis but sensitiv-
ity analyses were performed on key variables in the model.
RESULTS: The model estimated the direct medical cost (DMC)
at around €6.75 million/year (hospitalisation costs accounted for
64%), whilst indirect costs accounted for an additional €12
million/year. Threshold for being CE was set at ≤€50,000/QALY.
The analysis indicated that over a lifetime horizon vaccination
with RIX4414 is cost-effective including only DMC (€77.4/
dose). This strategy with the same price/dose induced cost
savings when also indirect costs were included in the equation.
Sensitivity analysis indicated that when emergency visits and hos-
pitalisation rates were substantially reduced (<20%) vaccination
was cost-effective when DMC and indirect costs were consid-
ered. CONCLUSIONS: RIX4414 vaccination is a cost-effective
strategy in a Belgian environment selecting a wide variety of sce-
narios in a societal perspective.
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OBJECTIVES: The Italian government recently banned embryo
cryopreservation for in vitro fertilization (IVF). The objective of
this study was to compare the cost effectiveness of IVF with 
and without the option of embryo freezing over three cycles of 
IVF from the Italian NHS perspective. METHODS: A decision 
analytical model was developed to evaluate the cost and cost-
effectiveness of two potential treatment approaches in couples
attempting IVF: (A) To perform three IVF fresh cycles including
the option of frozen embryo transfer; and (B) To perform three
IVF fresh cycles with no frozen embryo transfer. No treatment
was used as the reference strategy. Efﬁcacy data were derived
from clinical trials and the Italian IVF registry. A micro-costing
approach was used to determine the cost of fresh and frozen IVF
cycles. Drug costs and hospitalization costs were derived from
published sources. The primary outcome was measured in terms
of a live birth. Uncertainty surrounding the CE ratio was tested
using one-way sensitivity analysis. RESULTS: The model pre-
dicted a cumulative live birth rate after three completed IVF
cycles of 30.9% in the strategy using cryopreservation compared
to 25.3% in the IVF without cryopreservation approach. The
total cost per treatment was €4905 with the no frozen embryo
transfer strategy versus €5453 for the frozen embryo transfer.
The strategy to perform IVF without cryopreservation was
extensively dominated by the combination of no treatment and
IVF plus cryopreservation strategies. The incremental cost per
additional live birth was €21,863 for the IVF with embryo cry-
opreservation compared to the no treatment alternative. Results
were most sensitive to variations in the cost of an IVF treatment
cycle. CONCLUSIONS: Providing three cycles of IVF with the
frozen embryo option on the National Health Service in Italy
compares favorably to the option of allowing infertile couples
only three cycles of IVF.
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OBJECTIVES: To compare the clinical and cost-effectiveness of
dutasteride with placebo and ﬁnasteride in BPH. METHODS:
Systematic review according to Cochrane Collaboration guide-
lines and clinical effectiveness analysis according to Polish Phar-
macoeconomic Guidelines were performed. In the absence of
relevant head-to-head RCT dutasteride vs ﬁnasteride on clinical
hard endpoints, meta-analysis was performed using an indirect
comparison, with placebo as the common reference (Bucher
method). Cost-effectiveness Markov model was performed from
payer perspective (health insurance), using costs data from pub-
lished sources and a lifetime horizon. RESULTS: Dutasteride vs
placebo: 3 clinical trials were included. Dutasteride treatment
was associated with statistically signiﬁcantly greater reduction in
urological symptoms (AUA-SI scale) compared to placebo, with
difference in changes of 1.1, 1.4 and 2.2 points after 12, 18 and
24 months, respectively. There was statistically signiﬁcant dif-
ference in BPH Impact Index after 6 months (p < 0.005) and
after 24 months of follow-up (p < 0.001). Dutasteride signiﬁ-
cantly reduced risk of acute retention of urine (OR = 0.42),
prostate cancer (OR = 0.56) and necessity of surgical interven-
tion (OR = 0.51). Average costs (including costs of drugs, com-
plications and prostate cancer treatment) and effects (life-years
with no surgery/prostate cancer) were: dutasteride 5298 PLN/8
LY; placebo 2426 PLN/6.25 LY. ICER for dutasteride vs placebo
comparison was 1645 PLN/LY without surgery/Prostate cancer.
Dutasteride vs ﬁnasteride: 12 trials were included (1 direct and
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11 indirect comparisons). All the results were obtained from
indirect comparison. Dutasteride, compared to ﬁnasteride, sig-
niﬁcantly improved AUA-SI score (WMD = 1.53), and inﬂuenced
PSA concentration (WMD = −1.33). Average costs (including
drugs costs, complications and prostatic cancer treatment) and
effects (LY with no surgery/prostatic cancer) were per patient:
dutasteride 5655 PLN/6.23 LY; ﬁnasteride 6081 PLN/5.13 LY.
Dutasteride was dominant therapy compared with ﬁnasteride
(more effective and less costly). CONCLUSIONS: Dutasteride is
clinically more effective and more cost-effective in BPH com-
pared to both placebo and ﬁnasteride.
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OBJECTIVE: To evaluate the cost-effectiveness of IMSS formu-
lary drugs for preventing uterine atony in patients with risk
factors. METHODS: A ﬁnal report of a randomized pragmatic
clinical trial at the Mexican Institute of Social Security (IMSS) is
presented. Carbetocine and oxytocin are the only drugs within
IMSS formulary for preventing uterine atony. Risk factor
included fetal macrosomia, polyhydramnios, low insertion of the
placenta, multiple gestation, prolonged labor, uterine myomas
and chorioamnionitis. The effectiveness was deﬁned as the reduc-
tion of the number of patients with uterine atony. The use of
resources was obtained from the clinical trial and the costs were
gotten from ﬁnancial information from IMSS, and are expressed
in US 2006 dollars. Squared ji and U de Mann Whitney test were
used. Univariate and probabilistic sensitivity analyses, a Monte
Carlo microsimulation with 10,000 iterations was performed
using probability distribution data from the clinical trial. A 95%
conﬁdence interval of ICER was calculated by ellipse method.
RESULTS: Seventy-seven patients received carbetocine and 75
oxytocin. Both groups had similar obstetrics and sociodemo-
graphic characteristics. Uterine atony was reported in 19% in
the oxytocin group compared to 8% in the carbetocine one (p <
0.0001). Multiple gestation was the most frequent diagnosis,
35% (p < 0.0001). Bleeding was less than 500 mL in the carbe-
tocine group and 500–1000 mL in the oxytocin one (p < 0.0001).
Mean cost per patient treated with carbetocine was $3525 vs.
$4054 for oxytocine (p < 0.0001). Mean cost-effectiveness ratio
for oxytocin was $4944, while for carbetocine $3874; ICER
showed that carbetocine was dominant. Univariate analysis sup-
ported those results. The acceptability curve and health net ben-
eﬁts showed that carbetocine group was superior independently
of WTP. CI 99% by ellipse method showed that carbetocine was
dominant in 100% of cases. CONCLUSIONS: Carbetocine was
dominant in preventing uterine atony in patients with risk
factors.
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OBJECTIVE: As part of a health technology assessment com-
paring a single-embryo-transfer (SET) in In-Vitro Fertilization
(IVF) with the traditional double-embryo-transfer (DET) used
today in Denmark the cost-effectiveness of SET was compared
with DET. The aim was to inform decision-makers about the eco-
nomic consequences of the eventual adoption of a SET policy in
Denmark. METHODS: The analysis was based on prospective
collection of resource use and costs of singletons and twins. A
total of 213 pregnant women at the fertility clinic have been
reporting resource use (health care and so-cial sector), and days
absent from work in cost diaries during a year (from pregnancy
scan to until three months after delivery). Clinical effectiveness
data of SET and DET came from a Scandinavian multi-center
trial, and a recent Cochrane review. RESULTS: The advantage
of SET is delivery of few expensive twins compared with DET
(25%). The cost-effectiveness per clinical pregnancy of DET
(DKK 115,321 per clinical pregnancy and DKK 120,934 per
delivery) was lower than using that of SET (DKK 131,446 per
clinical pregnancy and DKK 149,833 per delivery). The cost-
effectiveness of DET is explained by a higher clinical pregnancy
rate, a higher rate of delivery, and more children born. However,
DET is also a more expen-sive alternative for the average patient
treated, because of higher costs for delivery and neonatal care.
The extra cost per patient using DET is around DKK 82,000 per
delivery and around DKK 50,000 per extra child born using
DET. CONCLUSION: The cost per delivery and per child born
is lower using DET compared with SER. However, the total costs
for DET is higher due to higher antenatal, delivery and neona-
tal costs, as well as production loss. A higher rate of twin deliv-
eries using DET explains this. These extra costs using the more
effective DET policy are moderate.
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Quantitative information on the management of PHN, a com-
plication of HZ, is scarce, with the most recent data from 1975.
With the imminent arrival of a prophylactic Zoster vaccine, it is
important to document the burden of PHN in the UK. OBJEC-
TIVES: To estimate the proportion of HZ patients developing
PHN, the duration, resource use and costs of PHN sufferers,
using two deﬁnitions: pain persisting one (1-month deﬁnition) or
three months (3-month deﬁnition) after HZ onset. METHODS:
Records of immuno-competent individuals of ≥50 years, diag-
nosed with HZ between 2000 and 2005, and with ≥1-year
follow-up were selected from the UK General Practice Research
Database (GPRD). PHN episodes were identiﬁed by formal diag-
nosis and prescriptions of typical neuropathic pain medications.
